# A Trial Of CVX-060, An Anti-Angiogenic COVX-Body, In Combination With Sunitinib In Patients With Advanced Renal Cell Carcinoma

> **NCT00982657** · PHASE2 · TERMINATED · sponsor: **Pfizer** · enrollment: 34 (actual)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** CVX-060 + sunitinib
- **DRUG:** CVX-060 + sunitinib
- **DRUG:** CVX-060 + sunitinib
- **DRUG:** CVX-060 + sunitinib
- **DRUG:** CVX-060 + sunitinib
- **DRUG:** Sunitinib

## Key facts

- **NCT ID:** NCT00982657
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-09
- **Primary completion:** 2014-03
- **Final completion:** 2014-03
- **Target enrollment:** 34 (ACTUAL)
- **Why stopped:** Refer to statement in Summary Section/Detailed Description
- **Last updated:** 2015-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00982657

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00982657, "A Trial Of CVX-060, An Anti-Angiogenic COVX-Body, In Combination With Sunitinib In Patients With Advanced Renal Cell Carcinoma". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00982657. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*